What was your consortium's most significant achievement from the past year?
Brendan Lee, MD, PhD, Principal Investigator, BBDC: Through the Brittle Bone Disorders Consortium (BBDC), investigators completed the systematic collection, harmonization, and analysis of the largest radiographic imaging cohort ever assembled for a rare bone disease population. This unique dataset, built through years of collaboration across sites, provides an unprecedented opportunity to characterize disease progression, skeletal outcomes, and clinical variability in osteogenesis imperfecta and related disorders. The resulting analyses establish a critical evidence base for developing disease-specific outcome measures and advancing future therapeutic studies.
What did this achievement accomplish?
Dr. Lee: The analysis transformed a large, longitudinal collection of imaging data into a valuable research resource capable of addressing clinically meaningful questions that were previously impossible to study at scale. By standardizing imaging assessments across participating sites, the consortium generated new insights into skeletal manifestations, disease progression, and variability across rare bone disease populations. This work also creates a foundation for identifying biomarkers and outcome measures that can be incorporated into future natural history studies and clinical trials. Importantly, it demonstrates the power of long-term multicenter collaboration to generate robust datasets that individual institutions could not assemble independently.
How will this impact the rare disease community?
Dr. Lee: Rare disease research is often limited by small patient populations and fragmented data. By creating and analyzing the largest radiographic cohort in rare bone disease, the consortium has established a resource that can improve disease characterization, support evidence-based clinical care, and accelerate therapeutic development. Patients, families, clinicians, and researchers will benefit from a deeper understanding of disease manifestations and progression. The dataset also provides industry and academic partners with critical information needed to design future studies, evaluate treatment effects, and identify meaningful endpoints for clinical trials, ultimately helping bring new therapies closer to patients.
How will this advance the goals of your consortium and/or the RDCRN at large?
Dr. Lee: This achievement directly supports the BBDC's mission to advance clinical trial readiness and improve outcomes for individuals with rare bone disorders. The imaging cohort provides essential infrastructure for future natural history studies, biomarker development efforts, and therapeutic trials. More broadly, it exemplifies RDCRN's core model of leveraging collaborative networks to generate high-impact datasets that would not be feasible at a single institution. By transforming long-term patient participation into actionable scientific knowledge, this work strengthens the rare disease research ecosystem and creates a platform for future discoveries, collaborations, and treatment development across the RDCRN community.
